本文關(guān)鍵詞： 利福昔明 復(fù)合乳酸菌膠囊 感染后腸易激綜合征 小腸細(xì)菌過(guò)度生長(zhǎng)　出處：《中國(guó)新藥雜志》2016年12期 　論文類(lèi)型：期刊論文

【摘要】：目的:探討利福昔明聯(lián)合復(fù)合乳酸菌膠囊對(duì)感染后腸易激綜合征(post-infection irritable bowel syndrome,PI-IBS)的臨床療效。方法:選取2014年1月至2015年6月就診我院消化內(nèi)科80例PI-IBS患者作為研究對(duì)象,隨機(jī)分為試驗(yàn)組和對(duì)照組各40例,對(duì)照組接受4周馬來(lái)酸曲美布汀片、復(fù)合乳酸菌膠囊治療,試驗(yàn)組接受2周利福昔明片、馬來(lái)酸曲美布汀片及復(fù)合乳酸菌膠囊治療后停用利福昔明片,繼續(xù)2周馬來(lái)酸曲美布汀片和復(fù)合乳酸菌膠囊治療,觀察兩組治療前后癥狀程度評(píng)分、血清炎性因子濃度變化,比較兩組治療總有效率、小腸細(xì)菌過(guò)度生長(zhǎng)轉(zhuǎn)陰率和不良反應(yīng)發(fā)生率。結(jié)果:兩組治療后癥狀程度評(píng)分明顯低于治療前(P0.05),且試驗(yàn)組治療后癥狀程度評(píng)分明顯低于對(duì)照組治療后癥狀程度評(píng)分(P0.05);兩組治療后血清促炎因子(IL-1β,IL-18)濃度明顯低于治療前(P0.05),抑炎因子IL-10濃度明顯高于治療前(P0.05),兩組之間比較,試驗(yàn)組治療后促炎因子(IL-1β,IL-18)濃度明顯低于對(duì)照組(P0.05),抑炎因子IL-10濃度明顯高于對(duì)照組(P0.05);試驗(yàn)組治療總有效率和小腸細(xì)菌過(guò)度生長(zhǎng)轉(zhuǎn)陰率均明顯高于對(duì)照組(P0.05);不良反應(yīng)發(fā)生率兩組差異無(wú)統(tǒng)計(jì)學(xué)意義(7.5%vs 5.0%,P0.05)。結(jié)論:利福昔明聯(lián)合復(fù)合乳酸菌膠囊治療感染后腸易激綜合征,能夠明顯緩解臨床癥狀,降低血清促炎因子濃度,升高抑炎因子濃度,提高治療總有效率和小腸細(xì)菌過(guò)度生長(zhǎng)轉(zhuǎn)陰率,安全有效。
[Abstract]:Objective: to study the effect of rifaximin combined with lactic acid bacteria capsule on post-infection irritable bowel syndrome of irritable bowel syndrome. Methods: from January 2014 to June 2015, 80 patients with PI-IBS in the Department of Gastroenterology in our hospital were selected as the study objects. They were randomly divided into two groups: the experimental group (n = 40) and the control group (n = 40). The control group received trimebutine maleate tablets for 4 weeks, and the experimental group received rifamethoxifen tablets for 2 weeks. Trimebutine maleate tablets and compound lactobacillus capsules were treated with trimebutine maleate and compound lactobacillus capsules for 2 weeks. The change of serum inflammatory factor concentration was compared with the total effective rate of the two groups. Results: the symptom score of the two groups after treatment was significantly lower than that before treatment (P 0.05). The scores of symptom degree after treatment in the test group were significantly lower than those in the control group (P 0.05). After treatment, the concentration of IL-1 尾 -IL-18 in serum of both groups was significantly lower than that before treatment, and the concentration of anti-inflammatory factor IL-10 was significantly higher than that of pre-treatment (P0.05). After treatment, the concentration of IL-1 尾 -IL-18 in the experimental group was significantly lower than that in the control group (P0.05). The concentration of anti-inflammatory factor IL-10 was significantly higher than that of control group (P 0.05). The total effective rate and overgrowth rate of intestinal bacteria in the experimental group were significantly higher than those in the control group (P 0.05). There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion: rifaximin combined with Lactobacillus capsule is effective in the treatment of irritable bowel syndrome after infection. It can obviously relieve the clinical symptoms, reduce the concentration of serum proinflammatory factor, increase the concentration of anti-inflammatory factor, improve the total effective rate of treatment and the rate of overgrowth of intestinal bacteria to negative, which is safe and effective.
【作者單位】： 安徽醫(yī)科大學(xué)海軍臨床學(xué)院;中國(guó)人民解放軍海軍總醫(yī)院消化內(nèi)科;
【基金】：吳階平臨床科研專(zhuān)項(xiàng)基金資助項(xiàng)目(320.6750.13175)
【分類(lèi)號(hào)】：R574
【正文快照】： 腸易激綜合征(irritable bowel syndrome,IBS)是一種常見(jiàn)的慢性功能性胃腸病(functional gastroin-testinal disorders,FGIDs),臨床特征為腹痛、腹脹等腹部不適,同時(shí)伴大便習(xí)慣和(或)大便性狀改變,而完善現(xiàn)有的一切檢查手段后未能發(fā)現(xiàn)可解釋上述癥狀的任何生化及解剖結(jié)構(gòu)異常[

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 吳楚璇;;復(fù)合乳酸菌膠囊在小兒腸道菌群失調(diào)性腹瀉中的應(yīng)用[J];醫(yī)學(xué)理論與實(shí)踐;2014年01期

2 唐細(xì)珍;;口服復(fù)合乳酸菌膠囊配合十六角蒙脫石保留灌腸治療小兒腹瀉的療效觀察及護(hù)理[J];全科護(hù)理;2010年04期

3 李志華;;復(fù)合乳酸菌膠囊聯(lián)合乳果糖治療便秘型腸易激綜合征的療效觀察[J];現(xiàn)代醫(yī)院;2013年10期

4 邱莉;廖翠芳;劉志祥;;乳果糖聯(lián)合復(fù)合乳酸菌治療嬰幼兒功能性便秘療效觀察[J];現(xiàn)代醫(yī)院;2013年03期

5 劉靜;盧向駿;;應(yīng)用復(fù)合乳酸菌膠囊治療小兒非細(xì)菌感染性腹瀉的療效觀察[J];當(dāng)代醫(yī)藥論叢;2014年10期

6 李雪萍;;復(fù)合乳酸菌佐治嬰幼兒腹瀉病的療效觀察[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2011年23期

7 吳建國(guó);復(fù)合乳酸菌膠囊治療腹瀉病療效觀察[J];實(shí)用兒科臨床雜志;2002年04期

8 劉兵;蘭永玲;苗曉艷;;思密達(dá)聯(lián)合復(fù)合乳酸菌膠囊治療小兒腹瀉的療效[J];中國(guó)醫(yī)藥指南;2011年31期

9 田春紅;吳榮初;;復(fù)合乳酸菌膠囊聯(lián)合思密達(dá)治療小兒腹瀉的療效觀察[J];中外醫(yī)學(xué)研究;2014年03期

10 宿軍;潘惠妮;李慎;馬麗霞;;復(fù)合乳酸菌聯(lián)用布拉氏酵母菌治療小兒腹瀉病療效觀察[J];廣州醫(yī)藥;2014年03期

相關(guān)博士學(xué)位論文 前1條

1 陳凌云;復(fù)合乳酸菌對(duì)不同營(yíng)養(yǎng)途徑治療的重癥急性胰腺炎大鼠腸屏障功能的影響及其機(jī)制研究[D];第二軍醫(yī)大學(xué);2006年

相關(guān)碩士學(xué)位論文 前3條

1 于佳弘;優(yōu)良乳酸菌的分離鑒定及復(fù)合菌粉制備工藝的研究[D];新疆農(nóng)業(yè)大學(xué);2015年

2 萬(wàn)榮峰;新型復(fù)合乳酸菌制劑的初步研究[D];南京農(nóng)業(yè)大學(xué);2005年

3 張濤;復(fù)合乳酸菌制劑抗柔嫩艾美耳球蟲(chóng)效果研究[D];吉林農(nóng)業(yè)大學(xué);2014年

，

本文編號(hào)：1484760